US FDA to decide fate of Genentech's pertuzumab by 8 June
This article was originally published in Scrip
Executive Summary
The US FDA will make a decision by 8 June on whether to approve Genentech's HER-dimerisation inhibitor pertuzumab as a treatment in combination with the firm's Herceptin (trastuzumab) plus docetaxel chemotherapy for patients with HER2-positive metastatic or locally recurrent, unresectable breast cancer who have not received previous treatment or whose disease has relapsed after adjuvant therapy, the South San Francisco-based company said.